肺部缓释微球治疗肺部疾病的性能及评价

Performance and evaluation of lung sustained-release microspheres for the treatment of lung diseases

背景:肺部因其特殊的生理结构而适合作为局部或全身用药的给药部位,而肺部缓释微球在肺部局部疾病治疗乃至全身疾病治疗方面的优越性尚缺乏更多的报道。目的:评价肺部缓释微球载体材料的释药性能以及临床给药途径的安全性,对比肺部缓释微球与其他肺部给药剂型的差异。方法:观察微球在肺部的分布及降解情况、肺组织的病理变化和连续给药对肺功能的影响。结果与结论:肺部缓释微球常用的材料有淀粉、聚乳酸等,具有生物可降解性、生物相容性和生物黏附性,并且缓释微球制备简单,对正常组织无损伤,安全性高,肺部缓释微球在体内有良好的肺靶向性,可提高药物的疗效,降低药物毒副作用,对肺组织无病理性损伤。

BACKGROUND： The lung is suitable as a local or systemic administration site because of its special physiological structure, while there lacks reports on advantages of lung sustained-release microspheres for the treatment of lung diseases, even systemic diseases. OBJECTIVE： To evaluate drug releasing property and safety of clinical administration of lung sustained-release microspheres, and to compare the difference between lung sustained-release microspheres and other pulmonary drug delivery dosage forms.METHODS： The distribution and degradation of microspheres in the lung, pathological changes of the lung tissue and the effect of continuous administration on lung function were observed. RESUTLS AND CONCLUSION： The materials commonly used for lung sustained-release microspheres included starch and polylactic acid. The lung sustained-release microspheres have the abilities of biodegradability, biocompatibility and bioadhesion. The sustained-release microspheres are easy to prepare and have no damage to the normal tissue with high security. The lung sustained-release microspheres have good lung targeting effects which can improve the drug efficacy, reduce the side effects of drugs and have no pathological damage to lung tissue.